Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VTYX Ventyx Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: VTYX
Price (delayed)
$1.7
Market cap
$120.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.75
Enterprise value
$102.47M
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2
Highlights
Ventyx Biosciences's EPS has increased by 46% YoY and by 11% from the previous quarter
VTYX's net income is up by 36% year-on-year and by 8% since the previous quarter
VTYX's quick ratio is down by 11% year-on-year but it is up by 8% since the previous quarter
Ventyx Biosciences's equity has decreased by 25% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of VTYX
Market
Valuations
Earnings
Shares outstanding
71.16M
Market cap
$120.97M
Enterprise value
$102.47M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.52
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$136.78M
Net income
-$123.99M
EBIT
-$123.99M
EBITDA
-$122.69M
Free cash flow
-$109.05M
Per share
Balance sheet
Liquidity
EPS
-$1.75
EPS diluted
-$1.75
Free cash flow per share
-$1.53
Book value per share
$3.26
Revenue per share
$0
TBVPS
$3.56
Total assets
$253.48M
Total liabilities
$21.85M
Debt
$10.55M
Equity
$231.63M
Working capital
$230.16M
Debt to equity
0.05
Current ratio
19.57
Quick ratio
18.54
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-43.5%
Return on equity
-47.4%
Return on invested capital
-51.3%
Return on capital employed
-51.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VTYX stock price
How has the Ventyx Biosciences stock price performed over time
Intraday
-6.08%
1 week
0.59%
1 month
27.82%
1 year
-64.66%
YTD
-22.37%
QTD
47.83%
Financial performance
How have Ventyx Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$136.78M
Net income
-$123.99M
Gross margin
N/A
Net margin
N/A
VTYX's net income is up by 36% year-on-year and by 8% since the previous quarter
The operating income is up by 34% year-on-year and by 8% since the previous quarter
Price vs fundamentals
How does VTYX's price correlate with its fundamentals
Growth
What is Ventyx Biosciences's growth rate over time
Valuation
What is Ventyx Biosciences stock price valuation
P/E
N/A
P/B
0.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Ventyx Biosciences's EPS has increased by 46% YoY and by 11% from the previous quarter
Ventyx Biosciences's equity has decreased by 25% YoY and by 9% from the previous quarter
The price to book (P/B) is 4% higher than the last 4 quarters average of 0.5
Efficiency
How efficient is Ventyx Biosciences business performance
The company's return on invested capital rose by 38% YoY and by 12% QoQ
Ventyx Biosciences's ROE has increased by 29% YoY
The company's return on assets rose by 28% YoY
Dividends
What is VTYX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VTYX.
Financial health
How did Ventyx Biosciences financials performed over time
VTYX's total assets is down by 24% YoY and by 8% from the previous quarter
VTYX's total liabilities is down by 13% YoY and by 3% from the previous quarter
The debt is 95% smaller than the equity
Ventyx Biosciences's equity has decreased by 25% YoY and by 9% from the previous quarter
The debt to equity is up by 25% QoQ and by 25% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.